EGFR and non-small cell lung carcinoma: Our study also did not provide the evidence that PC9-derived EV enhanced the sensitivity of EGFR wild-type to Osimertinib, which has been approved as the first line treatment in EGFR-mutant NSCLC by the FDA and EMA [38].